2023-03-21| Policy

HHS Issues Initial Guidance on Negotiation Program as Government’s Latest Move to Reduce Drug Prices

by Richard Chau
Share To
For the very first time in history, Medicare will be able to negotiate lower prescription drug prices since the passage of the Inflation Reduction Act by Congress last August and its signing by President Joe Biden.

The U.S. Department of Health and Human Services (HHS), through the Centers for Medicare & Medicaid Services (CMS), issued initial guidance on March 15 that details the requirements and parameters associated with crucial elements of the new Medicare Drug Price Negotiation Program and includes requests for public comment. The new negotiated prices will apply for the first time in 2026.

According to Xavier Becerra, Secretary of HHS, “Through the Medicare Drug Price Negotiation Program, we will make sure seniors get a fair price on Medicare’s costliest prescription drugs, promote competition in the market, and ensure Medicare is strong for beneficiaries today and into the future.”

It's free! Log in now to read

Accelerated Bio and Pluristyx Generate Clinical-Grade Induced Pluripotent Stem Cells from Reprogrammed Human Trophoblast Stem Cells
Novo Nordisk and PT Bio Farma Agree to Enhance Insulin Production for Diabetes Patients in Indonesia
Alzheimer’s Drug LEQEMBI Approved for Treatment in Hong Kong
Foreseen Biotech Strikes $1.03B Deal with Ipsen for First-in-Class ADC
Synthetic Biology’s Innovator Dr. John Cumbers – Addressing Inefficiencies in Biopharma and Economic Sustainability
Delivering Affordable Biologic Medicines Worldwide: An Interview with Tanvex Chairman and CEO, Henry Chen
Roche Secures CE Mark for AI-Powered Glucose Monitoring Solution, Enhancing Diabetes Care with Predictive Insights
Scroll to Top